trending Market Intelligence /marketintelligence/en/news-insights/trending/iyfsczktrriia5uqxzgalg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Canopy Growth to acquire US cannabis research company ebbu

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Canopy Growth to acquire US cannabis research company ebbu

Canada's Canopy Growth Corp. said it is going to acquire ebbu ebbu Inc., an Evergreen, Colo.-based hemp research company.

The Canadian medical cannabis company will pay C$25 million in cash and issue 6,221,210 of its common shares to ebbu, as well as up to C$100 million based on the achievement of certain milestones within two years after deal closing.

The acquisition of ebbu is meant to help bolster Canopy's research capabilities, particularly in the company's cannabis genetic breeding program and its cannabis-infused beverage offerings. By applying ebbu's intellectual property, Canopy could vastly reduce the cost of producing cannabidiol, the sought-after cannabis ingredient in the wellness and medical spaces.

Elsewhere, ebbu's expertise will also come in handy at Canopy's health-focused subsidiary Canopy Health Innovations which is developing cannabinoid-based clinical formulations for acute and chronic illnesses.

ebbu will continue to pursue R&D activities in the U.S. but will not produce or sell products resulting from such research unless it becomes federally legal to do so.

The acquisition, which is expected to close in November, is subject to regulatory approvals, including approvals by the Toronto Stock Exchange and New York Stock Exchange.